Literature DB >> 20556814

Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective.

Karen Herlyn1, Bernhard Hellmich, Philip Seo, Peter A Merkel.   

Abstract

OBJECTIVE: To assess patients' self-estimates of the burden of disease in vasculitis and to compare data across patient populations from the US, Germany, and the UK. Outcome assessment in vasculitis primarily focuses on physician evaluations of disease activity and damage. Little is known about the patients' perspectives regarding the burden of disease.
METHODS: Patients ranked (scale 0-5) a list of vasculitis-related items to estimate a combination of pain, interference with daily function, discomfort and/or annoyance, anxiety/psychological impact, and medical importance. Patients were also asked to list the 5 most troublesome aspects of the disease.
RESULTS: Data from 264 patients with vasculitis from 3 countries were collected. Wegener's granulomatosis was the predominant disease, comprising 63% of the cohort. Diagnoses were confirmed by physicians in 98% of cases. The most common item from the free-text sections was fatigue (75%), followed by pain (31%), musculoskeletal symptoms (24%), difficulty breathing (19%), financial aspects (13%), nasal discharge/crusting (14%), and weight gain (10%). Rankings of individual items varied substantially: fatigue (3.5), loss of energy (3.4), weight gain (3.1), joint pain (3.0), and sinusitis (3.0) were the highest-ranked symptoms among those manifestations experienced by at least 50% of patients. Several severe manifestations (e.g., dialysis, seizures, oxygen dependency) were ranked lower (<3.0).
CONCLUSION: Fatigue and reduced energy level are considered the most important disease burdens by patients with vasculitis; manifestations associated with organ damage were rated lower. The patients' perspectives of the impact of vasculitis differ from the physicians' ratings. Future outcome assessment in vasculitis should include the patients' perspectives.
Copyright © 2010 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2010        PMID: 20556814      PMCID: PMC3123033          DOI: 10.1002/acr.20276

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  25 in total

Review 1.  Patients and clinicians have different perspectives on outcomes in arthritis.

Authors:  Sarah A Hewlett
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

2.  Development and validation of a disease extent index for Wegener's granulomatosis.

Authors:  K de Groot; W L Gross; K Herlyn; E Reinhold-Keller
Journal:  Clin Nephrol       Date:  2001-01       Impact factor: 0.975

Review 3.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

Authors:  J C Jennette; R J Falk; K Andrassy; P A Bacon; J Churg; W L Gross; E C Hagen; G S Hoffman; G G Hunder; C G Kallenberg
Journal:  Arthritis Rheum       Date:  1994-02

4.  Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis.

Authors:  Maarten M Boomsma; Marc Bijl; Coen A Stegeman; Cees G M Kallenberg; Gary S Hoffman; Jan Willem Cohen Tervaert
Journal:  Arthritis Rheum       Date:  2002-04-15

5.  Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s.

Authors:  Nabih I Abdou; Glenn J Kullman; Gary S Hoffman; Gordon C Sharp; Ulrich Specks; Thomas McDonald; James Garrity; James A Goeken; Nancy B Allen
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

Review 6.  Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.

Authors:  Peter A Merkel; Philip J Clements; John D Reveille; Maria E Suarez-Almazor; Gabriele Valentini; Daniel E Furst
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

7.  Domains of health-related quality of life important to patients with giant cell arteritis.

Authors:  David B Hellmann; Misty L Uhlfelder; John H Stone; Mollie W Jenckes; Maria C Cid; Loic Guillevin; Larry Moreland; Paul F Dellaripa; Gary S Hoffman; Peter A Merkel; Robert Spiera; Lin Brown; José Hernández-Rodríguez; Haya R Rubin
Journal:  Arthritis Rheum       Date:  2003-12-15

8.  Determinants of discordance between patients and physicians in their assessment of lupus disease activity.

Authors:  Jim C Yen; Michal Abrahamowicz; Patricia L Dobkin; Ann E Clarke; Renaldo N Battista; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

9.  Wegener's granulomatosis: patient-reported effects of disease on health, function, and income.

Authors:  G S Hoffman; Y Drucker; M F Cotch; G A Locker; K Easley; K Kwoh
Journal:  Arthritis Rheum       Date:  1998-12

10.  Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis.

Authors:  Eva Reinhold-Keller; Karen Herlyn; Rosemarie Wagner-Bastmeyer; Joachim Gutfleisch; Hartmut H Peter; Heiner H Raspe; Wolfgang L Gross
Journal:  Arthritis Rheum       Date:  2002-06-15
View more
  35 in total

1.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

2.  Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers.

Authors:  Simon A Carter; Talia Gutman; Charlotte Logeman; Dan Cattran; Liz Lightstone; Arvind Bagga; Sean J Barbour; Jonathan Barratt; John Boletis; Dawn Caster; Rosanna Coppo; Fernando C Fervenza; Jürgen Floege; Michelle Hladunewich; Jonathan J Hogan; A Richard Kitching; Richard A Lafayette; Ana Malvar; Jai Radhakrishnan; Brad H Rovin; Nicole Scholes-Robertson; Hérnan Trimarchi; Hong Zhang; Karolis Azukaitis; Yeoungjee Cho; Andrea K Viecelli; Louese Dunn; David Harris; David W Johnson; Peter G Kerr; Paul Laboi; Jessica Ryan; Jenny I Shen; Lorena Ruiz; Angela Yee-Moon Wang; Achilles Hoi Kan Lee; Samuel Fung; Matthew Ka-Hang Tong; Armando Teixeira-Pinto; Martin Wilkie; Stephen I Alexander; Jonathan C Craig; Allison Tong
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-30       Impact factor: 8.237

3.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

4.  The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Haner Direskeneli; Karen Herlyn; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Raashid A Luqmani
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

5.  Causal attributions about disease onset and relapse in patients with systemic vasculitis.

Authors:  Peter C Grayson; Naomi A Amudala; Carol A McAlear; Renée L Leduc; Denise Shereff; Rachel Richesson; Liana Fraenkel; Peter A Merkel
Journal:  J Rheumatol       Date:  2014-03-15       Impact factor: 4.666

6.  The Rare Diseases Clinical Research Network's organization and approach to observational research and health outcomes research.

Authors:  Jeffrey P Krischer; Rashmi Gopal-Srivastava; Stephen C Groft; David J Eckstein
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

7.  OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Authors:  Joanna C Robson; Gunnar Tomasson; Nataliya Milman; Sue Ashdown; Annelies Boonen; George C Casey; Peter F Cronholm; David Cuthbertson; Jill Dawson; Haner Direskeneli; Ebony Easley; Tanaz A Kermani; John T Farrar; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Alfred Mahr; Carol A McAlear; Jacqueline Peck; Beverley Shea; Judy A Shea; Antoine G Sreih; Peter S Tugwell; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

8.  Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health.

Authors:  Nataliya Milman; Eilish McConville; Joanna C Robson; Annelies Boonen; Peter Tugwell; George A Wells; Dipayan Chaudhuri; Jill Dawson; Gunnar Tomasson; Susan Ashdown; Don Gebhart; Georgia Lanier; Jacqueline Peck; Carol A McAlear; Katherine S Kellom; Peter F Cronholm; Peter A Merkel
Journal:  J Rheumatol       Date:  2019-02-01       Impact factor: 4.666

Review 9.  Patient-reported outcomes in core domain sets for rheumatic diseases.

Authors:  Lilian H D van Tuyl; Maarten Boers
Journal:  Nat Rev Rheumatol       Date:  2015-09-01       Impact factor: 20.543

Review 10.  Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Authors:  Joanna C Robson; Nataliya Milman; Gunnar Tomasson; Jill Dawson; Peter F Cronholm; Katherine Kellom; Judy Shea; Susan Ashdown; Maarten Boers; Annelies Boonen; George C Casey; John T Farrar; Don Gebhart; Jeffrey Krischer; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Antoine G Sreih; Peter S Tugwell; Raashid A Luqmani; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-09-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.